Please wait a minute...
文章检索
预防医学  2026, Vol. 38 Issue (7): 726-730    DOI: 10.19485/j.cnki.issn2096-5087.2026.07.019
  疾病控制 本期目录 | 过刊浏览 | 高级检索 |
2015—2025年安吉县5种主要消化系统恶性肿瘤死亡及寿命损失分析
曹乙, 丁炀, 邓方缘, 刘晶晶
安吉县疾病预防控制中心(安吉县卫生监督所),浙江 安吉 313000
Mortality and years of life lost of five major digestive system malignant tumors in Anji County from 2015 to 2025
CAO Yi, DING Yang, DENG Fangyuan, LIU Jingjing
Anji County Center for Disease Control and Prevention (Anji County Institute of Public Health Supervision),Anji, Zhejiang 313000, China
全文: PDF(876 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 分析2015—2025年浙江省安吉县5种主要消化系统恶性肿瘤死亡趋势及寿命损失,为完善消化系统恶性肿瘤防控策略提供参考。方法 通过浙江省慢性病监测信息管理系统收集2015—2025年安吉县消化系统恶性肿瘤死亡资料,计算粗死亡率,采用2000年第五次全国人口普查数据计算标化死亡率;采用潜在减寿年数(PYLL)、平均减寿年数(AYLL)和潜在减寿率(PYLLR)分析寿命损失。采用平均年度变化百分比(AAPC)分析2015—2025年消化系统恶性肿瘤死亡率变化趋势。结果 2015—2025年安吉县消化系统恶性肿瘤死亡4 133例,粗死亡率为79.67/10万,标化死亡率为34.75/10万;肝癌、结直肠癌、胃癌、胰腺癌和食管癌死亡3 957例,占95.74%,粗死亡率分别为19.68/10万、19.14/10万、16.25/10万、12.07/10万和9.14/10万。2015—2025年肝癌、胃癌、食管癌和结直肠癌标化死亡率呈下降趋势(AAPC=-6.647%、-8.021%、-7.788%和-2.087%,均P<0.05),胰腺癌趋势无统计学意义(P>0.05)。男性肝癌、结直肠癌、胃癌、胰腺癌和食管癌粗死亡率分别为27.19/10万、23.96/10万、23.85/10万、13.54/10万和15.44/10万,高于女性的12.30/10万、14.40/10万、8.79/10万、10.62/10万和2.94/10万(均P<0.05)。随着年龄增长,肝癌、结直肠癌、胃癌和食管癌均在≥85岁组达峰值,胰腺癌在80~<85岁组达峰值。5种主要消化系统恶性肿瘤的PYLL为16 015.00人年,AYLL为9.84年/人,PYLLR为3.48‰,其中肝癌的PYLL、AYLL和PYLLR均较高,分别为5 490.00人年、10.98年/人和1.19‰。结论 2015—2025年安吉县肝癌、结直肠癌、胃癌和食管癌标化死亡率下降,但胰腺癌变化平缓;肝癌寿命损失较严重;男性、老年人是重点防控对象。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
曹乙
丁炀
邓方缘
刘晶晶
关键词 消化系统恶性肿瘤死亡率寿命损失平均年度变化百分比    
AbstractObjective To analyze the mortality trends and years of life lost of five major digestive system malignant tumors in Anji County, Zhejiang Province, from 2015 to 2025, so as to provide reference for improving prevention and control measures for digestive system malignant tumors. Methods Data on deaths from digestive system malignant tumors among residents in Anji County from 2015 to 2025 were collected through Zhejiang Provincial Chronic Disease Surveillance Information Management System, and the crude mortality were calculated. Age-standardized mortality was calculated using data from the fifth National Population Census in 2000. Potential years of life lost (PYLL), average years of life lost (AYLL), and potential years of life lost rate (PYLLR) were used to analyze years of life lost. The average annual percent change (AAPC) was used to analyze the trends in mortality from digestive system malignant tumors from 2015 to 2025. Results From 2015 to 2025, a total of 4 133 deaths from digestive system malignant tumors were reported in Anji County. The crude mortality was 79.67/105, and the age-standardized mortality was 34.75/105. A total of 3 957 deaths were attributed to liver cancer, colorectal cancer, gastric cancer, pancreatic cancer, and esophageal cancer, accounting for 95.74% of all cancer-related deaths. The corresponding crude mortality were 19.68/105, 19.14/105, 16.25/105, 12.07/105, and 9.14/105, respectively. From 2015 to 2025, the age-standardized mortality of liver cancer, gastric cancer, esophageal cancer, and colorectal cancer showed downward trends (AAPC=-6.647%, -8.021%, -7.788%, and -2.087%, all P<0.05), while the trend for pancreatic cancer was not statistically significant (P>0.05). The crude mortality of liver cancer, colorectal cancer, gastric cancer, pancreatic cancer, and esophageal cancer in males were 27.19/105, 23.96/105, 23.85/105, 13.54/105, and 15.44/105, respectively, while the corresponding rates in females were 12.30/105, 14.40/105, 8.79/105, 10.62/105, and 2.94/105, respectively (all P<0.05). With increasing age, the mortality of liver cancer, colorectal cancer, gastric cancer, and esophageal cancer peaked in the ≥85 years age group, while pancreatic cancer peaked in the 80-<85 years age group. The PYLL of the five major digestive system malignant tumors was 16 015.00 person-years, the AYLL was 9.84 years per person, and the PYLLR was 3.48‰. Among them, liver cancer had relatively high PYLL (5 490.00 person-years), AYLL (10.98 years per person), and PYLLR (1.19‰). Conclusions From 2015 to 2025, the age-standardized mortality of liver cancer, colorectal cancer, gastric cancer, and esophageal cancer in Anji County generally declined, while that of pancreatic cancer remained relatively stable. Liver cancer recorded a relatively high years of life lost. Males and the elderly remain the key populations for prevention and control.
Key wordsdigestive system malignant tumor    mortality    years of life lost    average annual percent change
收稿日期: 2026-03-17      修回日期: 2026-07-06      出版日期: 2026-07-10
中图分类号:  R735  
作者简介: 曹乙,本科,副主任医师,主要从事慢性病预防与控制工作,E-mail:caoyi_00@126.com
引用本文:   
曹乙, 丁炀, 邓方缘, 刘晶晶. 2015—2025年安吉县5种主要消化系统恶性肿瘤死亡及寿命损失分析[J]. 预防医学, 2026, 38(7): 726-730.
CAO Yi, DING Yang, DENG Fangyuan, LIU Jingjing. Mortality and years of life lost of five major digestive system malignant tumors in Anji County from 2015 to 2025. Preventive Medicine, 2026, 38(7): 726-730.
链接本文:  
https://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2026.07.019      或      https://www.zjyfyxzz.com/CN/Y2026/V38/I7/726
[1] 王嘉琛,何思怡,曹梦迪,等.1990—2021年中国人群5种常见消化系统恶性肿瘤疾病负担变化趋势分析[J].中华消化外科杂志,2025,24(2):213-222.
[2] Qi J L,Li M L,Wang L J,et al.National and subnational trends in cancer burden in China,2005-20:an analysis of national mortality surveillance data[J].Lancet Public Heal,2023,8(12):943-955.
[3] Han B F,Zheng R S,Zeng H M,et al.Cancer incidence and mortality in China,2022[J].J Natl Cancer Cent,2024,4(1):47-53.
[4] 曹梦迪,陈万青.GLOBOCAN 2022全球癌症统计数据解读[J/OL].中国医学前沿杂志(电子版),2024,16(6):1-5.
[5] Zhou Y Y,Song K,Chen Y Q,et al.Burden of six major types of digestive system cancers globally and in China[J].Chin Med J,2024,137(16):1957-1964.
[6] 杜灵彬,邱雨,李辉章,等.2021年浙江省肿瘤登记地区恶性肿瘤发病和死亡特征分析[J].预防医学,2025,37(10):973-978.
[7] 舒奇,夏文霞,李振娟,等.2003—2023年金山区居民伤害死亡与减寿趋势分析[J].预防医学,2026,38(2):156-160,165.
[8] 沈惠,郭燕.2010—2019年武汉市消化系统恶性肿瘤的死亡趋势与年龄-时期-队列模型分析[J].中国慢性病预防与控制,2025,33(4):296-302.
[9] 郑婉辉.2014—2020年福州市居民消化系统恶性肿瘤死亡状况分析[J].慢性病学杂志,2022,23(2):168-172.
[10] 中华人民共和国国家统计局.中华人民共和国2025年国民经济和社会发展统计公报[EB/OL].[2026-07-06].https://www.stats.gov.cn/sj/zxfb/202602/t20260228_1962662.html.
[11] 郑雨虹,周海茸,杨华凤,等.2007—2019年江苏省南京市消化系统恶性肿瘤死亡特征与趋势分析[J].中国肿瘤,2021,30(12):919-925.
[12] Xu Y J,Xia C F,Wang J C,et al.Divergent trends in the burden of esophageal,gastric,and liver cancers in China[J].J Natl Cancer Cent,2025,5(3):306-312.
[13] 中华医学会肿瘤学分会早诊早治学组.中国结直肠癌早诊早治专家共识(2023版)[J].中华医学杂志,2023,103(48):3896-3908.
[14] 丁晶莹,俞梅华.2013—2020年浙江省湖州市胰腺癌死亡趋势及寿命损失分析[J].疾病监测,2022,37(5):679-683.
[15] 贺宇彤,郑荣寿,孙喜斌,等.中国恶性肿瘤性别发病差异分析[J].中国肿瘤,2013,22(3):174-179.
[16] Jackaman C,Tomay F,Duong L,et al.Aging and cancer:The role of macrophages and neutrophils[J].Ageing Res Rev,2017,36:105-116.
[17] 孙晓伟,苏彦萍,刘庆萍,等.2010—2023年北京市通州区消化道恶性肿瘤死亡流行特征及疾病负担分析[J].中华肿瘤防治杂志,2025,32(7):393-398.
[1] 王诚, 王小红, 周凡. 2016—2024年金华市甲状腺癌发病变化趋势分析[J]. 预防医学, 2026, 38(7): 657-660,665.
[2] 任露露, 闵艺璇, 顾嘉昌, 张思晨, 乔健健, 胡静. 2013—2022年宜兴市肺癌发病和死亡变化趋势分析[J]. 预防医学, 2026, 38(7): 675-679,685.
[3] 朱跃蒙, 倪朝荣, 谢华森, 李晓伟, 余向华, 黄洁茹. 2015—2025年温州市其他感染性腹泻流行特征分析[J]. 预防医学, 2026, 38(7): 703-705,710.
[4] 胡蔡松, 余向华, 魏晶娇, 高豪俊, 李万仓, 王冰倩, 叶振淼. 2012—2024年温州市水痘流行特征分析[J]. 预防医学, 2026, 38(7): 711-713.
[5] 徐露婷, 田雨涵, 蒲焱. 贵阳市恶性肿瘤疾病负担分析[J]. 预防医学, 2026, 38(5): 517-522.
[6] 姜雪霞, 叶振淼, 樊丽辉, 郑宇航, 罗永园, 李慧君, 夏喆铮. 2015—2022年温州市女性乳腺癌发病趋势分析[J]. 预防医学, 2026, 38(5): 478-482.
[7] 李景琦, 李晨曦, 董立平. 1994—2023年中国脑卒中发病和死亡的年龄-时期-队列分析[J]. 预防医学, 2026, 38(5): 488-492,497.
[8] 冯豪, 李广辉, 田阳阳, 葛锐. 2015—2024年嘉兴市生殖道沙眼衣原体感染流行特征及趋势分析[J]. 预防医学, 2026, 38(5): 493-497.
[9] 曹元, 沈钲杰, 谢开婿. 2015—2024年桐乡市结直肠癌发病和死亡趋势分析[J]. 预防医学, 2026, 38(5): 536-540.
[10] 韦艳炼, 农圣, 漆光紫, 江建明. 1990—2023年中国肝癌疾病负担变化趋势及年龄-时期-队列分析[J]. 预防医学, 2026, 38(5): 473-477.
[11] 张爱平, 袁芳, 蔡一飙, 岑焕新, 潘劲. 2014—2023年江北区冠心病死亡特征及趋势分析[J]. 预防医学, 2026, 38(5): 504-507,512.
[12] 金茜, 叶振淼, 姜雪霞, 樊丽辉, 张默涵, 谢轶敏, 罗永园, 郑宇航. 2016—2023年温州市糖尿病发病趋势分析[J]. 预防医学, 2026, 38(4): 372-376.
[13] 杨慧, 张以祥, 赵梅玲. 2006—2024年洪泽区HIV/AIDS病例特征分析[J]. 预防医学, 2026, 38(4): 402-405.
[14] 李海华, 叶勇, 袁瑞, 运靖宜, 王浩博, 傅雨欣. 2006—2025年湖州市儿童青少年糖尿病发病趋势及年龄-时期-队列分析[J]. 预防医学, 2026, 38(3): 257-262.
[15] 闫瑞平, 李建彬, 安戈, 郭向娇, 黄婼璇, 宋彩娟. 2016—2021年郑州市肿瘤登记地区甲状腺癌发病和死亡趋势分析[J]. 预防医学, 2026, 38(3): 267-273.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed